NCT03193554

Diagnostic Value of MicroRNA 210 In Preeclampsia

Status unknown Last updated 12 May 2020

What this trial tests

trial in Pre-Eclampsia in 80 participants. Status unknown.

Timeline

1 January 2019

Primary endpoint
1 May 2020

30 August 2020

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	80
Start date	1 January 2019
Primary completion	1 May 2020
Estimated completion	30 August 2020
Sites	2 locations across Egypt

Conditions studied

• Pre-Eclampsia — all drugs for Pre-Eclampsia →

Sponsor

Assiut University

Who can join

Adults 20 to 40, female only, with Pre-Eclampsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pre-eclampsia is a disorder of pregnancy characterized by hypertension (defined as systolic blood pressure 140mmHg or diastolic blood pressure ⩾90 mmHg) and proteinuria (300 mg or greater in a 24 h urine specimen and/or protein to creatinine ratio of \> 0.30) . The disorder usually occurs after 20 weeks of pregnancy and worsens over time. Risk factors for pre-eclampsia include: obesity, prior hypertension, older age, and diabetes mellitus, primigravida and pregnant women with multiple gestation .

Healthy women pregnancy can be associated with resistance to the action of insulin on glucose uptake and utilization. Insulin Resistance (IR) is defined as decreased ability of target tissues such as liver, adipose tissue and muscle to respond to normal circulating concentrations of insulin. Insulin Resistance can be a result of a number of factors such as defective molecular structure of insulin, defective receptor functioning or defective signal transduction pathway .

Preeclampsia is associated with increased expression of Tumor necrosis Factor α and other inflammatory marker which causes Insulin Resistance. Increased Insulin Resistance leads to dyslipidemia that can worsen the placental ischemia leading to vicious cycle of ischemia-inflammation-Insulin Resistance-dyslipidemia-ischemia . Insulin resistance has also been hypothesized to contribute to the pathophysiology of preeclampsia. Compared to women who have normotensive pregnancies, women who develop preeclampsia are more insulin resistant prior to pregnancy .

The recognition that specific miRNAs are induced by hypoxia and are commonly dysregulated in preeclampsia raises the possibility that such miRNAs mediate the adverse effects of placental hypoxia in preeclampsia. MiRNAs present in maternal blood may have the potential to be used as biomarkers, as they are relatively stable and tissue specific . It was found that mir-210 is induced in patients with pre-eclampsia, whether mir-210 contributes to the pathogenesis of pre-eclampsia, a complex disorder widely believed to be associated with placental hypoxia .

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: The Path From Bench to Bedside.
   Zhou LY, Lin SN, Rieder F, Chen MH, et al · · 2021 · cited 11× · PMID 33324986 · DOI 10.1093/ibd/izaa321